Generics - Generics, Anti-Arthritics/Rheumatics


Popular Filters

1 to 25 of 34 results

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin

Sandoz fails in patent suit with Amgen over Enbrel; Cubist prevails over Cubicin


US biotech giant Amgen saw its shares rise 1.9% to $172.00 yesterday after the top US patent appeal court…

AmgenAnti-Arthritics/RheumaticsAntibiotics and Infectious diseasesBiosimilarsCubicinCubist PharmaceuticalsEnbrelGenericsHospiraLegalNovartisPatentsSandozUSA

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan


Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

New analysis of potential savings from Biosimilars in USA

New analysis of potential savings from Biosimilars in USA


Introducing competing “biosimilar” versions of complex biologic drugs used to treat illnesses such…


Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio

Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio


German generic and branded drugmaker Stada Arzneimittel has in-licensed osteoporosis drug teriparatide,…

Anti-Arthritics/RheumaticsBiosimilarsEli LillyForsteoGenericsLicensingRichter-Helm BioTecSTADA Arzneimittelteriparatide

EPIRUS and Livzon Mabpharm to develop biosimilars for China

EPIRUS and Livzon Mabpharm to develop biosimilars for China


EPIRUS Biopharmaceuticals has signed a royalty-bearing, multi-product collaboration agreement with Livzon…

Anti-Arthritics/RheumaticsBiosimilarsBOW015ChinaEPIRUS BiopharmaceuticalsGastro-intestinalsGenericsLicensingLivzon MabpharmRemicadeResearch

Actavis settles Celebrex patent challenge with Pfizer


Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…


Teva and Pfizer settle patent litigation over Celebrex


Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

Prasco to market the authorized generic of Lilly’s Evista in USA


Privately-held US generics firm Prasco has signed a further deal with US pharma major Eli Lilly to market…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsMarkets & MarketingNorth AmericaPrasco LaboratoriesUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA


Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

Actavis challenges Multaq and Colcrys patents


Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Rapid uptake of rheumatoid arthritis biosimilars expected in Brazil and Mexico


Biosimilars will be quickly acquired and used in public health institutions in the treatment of patients…

Anti-Arthritics/RheumaticsBiosimilarsBrazilGenericsMarkets & MarketingRegulationSouth America

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond

Report: Approval of first biosimilar MAb in Europe has major implications for 2014 and beyond


Key clinical, corporate and regulatory events affecting the biosimilar industry have been identified…

Anti-Arthritics/RheumaticsBiosimilarsCellTrionEuropeGenericsHospiraInflammatory diseasesInflectraMarkets & MarketingRegulationRemsima

EGA welcomes first biosimilar MAb approvals in Europe


Following the European Medicines Agency's CHMP recommendation, the European Commission (EC) has just…


First biosimilar monoclonal antibody approved in Europe


US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Baxter and Coherus in up to $246 million deal for biosimilar etanercept


US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Phase III data support biosimilarity of BOW-015 to Remicade


Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

Horizon Pharma in Duexis patent settlement


Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

US FDA accepts Pennsaid 2% NDA for review


The US Food and Drug Administration has accepted for filing US drugmaker Mallinckrodt's (NYSE: MNK) New…

Anti-Arthritics/RheumaticsGenericsMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

EMA's CHMP backs approval of first two monoclonal antibody biosimilars of blockbuster Remicade


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRegulationRemsima

Sandoz initiates Ph III trial for biosimilar Enbrel


Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…


Generics triple-therapy just as effective as brand-name Enbrel, new study shows


Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…


Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar


USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

1 to 25 of 34 results

Back to top